Introduction
BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT1A receptor agonist.
It also has affinity for the 5-HT2 and D4 receptors.
The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.
This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/BMY-14802 >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.
Mental Health Matters 